Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 3—March 2007
Research

Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1

Stephen Mark Tompkins*1Comments to Author , Zi-Shan Zhao*, Chia-Yun Lo*, Julia A. Misplon*, Teresa Liu*, Zhiping Ye*, Robert J. Hogan†, Zhengqi Wu*, Kimberly A. Benton*, Terrence M. Tumpey‡, and Suzanne L. Epstein*
Author affiliations: *Food and Drug Administration, Bethesda, Maryland, USA; †University of Georgia, Athens, Georgia, USA; ‡Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Table

Sequences of matrix protein 2 (M2) ectodomains

StrainAbbreviationSubtypeM2e Sequence*†
Consensus
M2e-con
‡
MSLLTEVETPIRNEWGCRCNDSSD
A/PR/8
M2e-PR8
H1N1
MSLLTEVETPIRNEWGCRCNGSSD
A/FM/1/47-MA
M2e-FM
H1N1
MSLLTEVETPTKNEWECRCNDSSD
A/HK/156/97
M2e-H5(HK)
H5N1
MSLLTEVETLTRNGWGCRCSDSSD
A/Thailand/SP-83/04M2e-H5(SP-83)H5N1MSLLTEVETPTRNEWECRCSDSSD

*Variations from the M2e consensus sequence are in boldface.
†Virus sequences available at www.ncbi.nlm.nih.gov/genomes/FLU and www.flu.lanl.gov
‡Consensus sequence derived from human influenza viruses of H1, H2, and H3 subtypes (9,13).

Main Article

References
  1. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Heterologous protection against influenza by injection of DNA encoding a viral protein.Science. 1993;259:1745–9. DOIPubMedGoogle Scholar
  2. Epstein SL, Stack A, Misplon JA, Lo CY, Mostowski H, Bennink J, Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge.Int Immunol. 2000;12:91–101. DOIPubMedGoogle Scholar
  3. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.Emerg Infect Dis. 2002;8:796–801.PubMedGoogle Scholar
  4. Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley, PM, Griffin DE, Martin MA, Lamb RA, Roizman B, et al., editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1487–503.
  5. Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions.J Virol. 1988;62:2762–72.PubMedGoogle Scholar
  6. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.Vaccine. 2004;22:2993–3003. DOIPubMedGoogle Scholar
  7. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein.Vaccine. 1995;13:1399–402. DOIPubMedGoogle Scholar
  8. Frace AM, Klimov AI, Rowe T, Black RA, Katz JM. Modified M2 proteins produce heterotypic immunity against influenza A virus.Vaccine. 1999;17:2237–44. DOIPubMedGoogle Scholar
  9. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein.Nat Med. 1999;5:1157–63. DOIPubMedGoogle Scholar
  10. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos JL, Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.Vaccine. 2003;21:2616–26. DOIPubMedGoogle Scholar
  11. Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K, Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene.Vaccine. 2001;19:3681–91. DOIPubMedGoogle Scholar
  12. Watabe S, Xin K-Q, Ihata A, Liu L-J, Honsho A, Aoki I, Protection against influenza virus challenge by topical application of influenza DNA vaccine.Vaccine. 2001;19:4434–44. DOIPubMedGoogle Scholar
  13. Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.J Virol. 2005;79:6644–54. DOIPubMedGoogle Scholar
  14. Liu W, Zou P, Ding J, Lu Y, Chen YH. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design.Microbes Infect. 2005;7:171–7. DOIPubMedGoogle Scholar
  15. Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, Cramer DV, Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines.Vaccine. 2006;24:5158–68. DOIPubMedGoogle Scholar
  16. Smeenk CA, Brown EG. The influenza virus variant A/FM/1/47-MA possesses single amino acid replacements in the hemagglutinin, controlling virulence, and in the matrix protein, controlling virulence as well as growth.J Virol. 1994;68:530–4.PubMedGoogle Scholar
  17. World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia.Emerg Infect Dis. 2005;11:1515–21.PubMedGoogle Scholar
  18. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.Vaccine. 2005;23:5404–10. DOIPubMedGoogle Scholar
  19. Huang X, Liu T, Muller J, Levandowski RA, Ye Z. Effect of influenza virus matrix protein and viral RNA on ribonucleoprotein formation and nuclear export.Virology. 2001;287:405–16. DOIPubMedGoogle Scholar
  20. Benton KA, Misplon JA, Lo CY, Brutkiewicz RR, Prasad SA, Epstein SL. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells.J Immunol. 2001;166:7437–45.PubMedGoogle Scholar
  21. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.J Immunol. 2004;172:5598–605.PubMedGoogle Scholar
  22. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza.J Infect Dis. 2003;188:57–61. DOIPubMedGoogle Scholar

Main Article

1Current affiliation: University of Georgia, Athens, Georgia, USA

Page created: June 29, 2010
Page updated: June 29, 2010
Page reviewed: June 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external